Loading clinical trials...
Loading clinical trials...
A Single Center, Open Label, Multiple-Dose Oral Oseltamivir Suspension Study in End-Stage-Renal Disease (ESRD) Patients on Hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD)
Conditions
Interventions
Oseltamivir
Locations
1
New Zealand
Christchurch, New Zealand
Start Date
October 1, 2001
Primary Completion Date
June 1, 2002
Completion Date
June 1, 2002
Last Updated
February 15, 2016
NCT07146854
NCT04163614
NCT04580420
NCT06190717
NCT05654103
NCT03994471
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions